Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
Standard
Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. / Harter, Philipp; Hilpert, Felix; Mahner, Sven; Heitz, Florian; Pfisterer, Jacobus; Andreas, Du Bois.
in: EXPERT REV ANTICANC, Jahrgang 10, Nr. 1, 1, 01.01.2010, S. 81-88.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
AU - Harter, Philipp
AU - Hilpert, Felix
AU - Mahner, Sven
AU - Heitz, Florian
AU - Pfisterer, Jacobus
AU - Andreas, Du Bois
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Most patients with ovarian cancer relapse despite aggressive surgery and platinum-taxane-based primary chemotherapy. Further treatment depends on prior response and progression-free interval. Monotherapy is indicated in patients with so-called platinum-resistant or -refractory ovarian cancer. The standard treatment for patients with platinum-sensitive recurrent ovarian cancer is platinum-based combination chemotherapy. Cytoreductive surgery is also a treatment option in such patients. Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer.
AB - Most patients with ovarian cancer relapse despite aggressive surgery and platinum-taxane-based primary chemotherapy. Further treatment depends on prior response and progression-free interval. Monotherapy is indicated in patients with so-called platinum-resistant or -refractory ovarian cancer. The standard treatment for patients with platinum-sensitive recurrent ovarian cancer is platinum-based combination chemotherapy. Cytoreductive surgery is also a treatment option in such patients. Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer.
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Disease-Free Survival
KW - Drug Resistance, Neoplasm
KW - Female
KW - Humans
KW - Neoplasm Recurrence, Local
KW - Ovarian Neoplasms
KW - Time Factors
KW - Treatment Outcome
U2 - 10.1586/era.09.165
DO - 10.1586/era.09.165
M3 - SCORING: Journal article
C2 - 20014888
VL - 10
SP - 81
EP - 88
JO - EXPERT REV ANTICANC
JF - EXPERT REV ANTICANC
SN - 1473-7140
IS - 1
M1 - 1
ER -